Eli Lilly to buy Loxo Oncology for $8 billion
Eli Lilly has announced its intention to buy pioneering cancer treatment development company Loxo Oncology in a deal worth approximately $8 billion.
Read More
Tag: deal
Takeda completes Shire acquisition
Takeda has completed its £46-billion acquisition of Shire, a deal that took just eight months to see through from announcement to close.
Read More
Bristol-Myers Squibb to buy Celgene
Bristol-Myers Squibb has unveiled its intent to acquire Celgene in a deal worth $74 billion, in order to “create a premier innovative biopharma company”.
Read More
NHS set to save record £300 million on highest drug spend
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
